Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22265565 | 1.00 | RAB9A (0.65) | RAB9AGAANPC1LMNATP53 | |
| SCHEMBL7294953 | 0.84 | GAA (0.56) | RAB9AGAANPC1LMNATP53 | |
| SCHEMBL7301072 | 0.83 | PARP10 (0.66) | RAB9AGAANPC1LMNATP53 | |
| Pentamidine Dao SCHEMBL8653348 | 0.82 | GAA (0.84) | RAB9AGAANPC1LMNATP53 | |
| SCHEMBL14599647 | 0.82 | GAA (0.84) | RAB9AGAANPC1LMNATP53 | |
| SCHEMBL14599648 | 0.82 | GAA (0.84) | RAB9AGAANPC1LMNATP53 | |
| SCHEMBL14599580 | 0.82 | GAA (0.84) | RAB9AGAANPC1LMNATP53 | |
| Pentamidine Dao SCHEMBL12355833 | 0.82 | GAA (0.84) | RAB9AGAANPC1LMNATP53 | |
| Pentamidine Dao SCHEMBL12348101 | 0.82 | GAA (0.84) | RAB9AGAANPC1LMNATP53 | |
| SCHEMBL14599579 | 0.82 | GAA (0.84) | RAB9AGAANPC1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0504574-B1 | 1,2,4-Oxadiazole derivatives having monoamine oxidase B enzyme-inhibitory activity and method for preparing same | WAKAMOTO PHARMA CO LTD (JP) | 1996-02-28 | — | — | EP | claimed |
| EP-0504574-A1 | 1,2,4-Oxadiazole derivatives having monoamine oxidase B enzyme-inhibitory activity and method for preparing same | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1992-09-23 | — | — | EP | claimed |
| US-12590083-B2 | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-31 | — | — | US | disclosed |
| US-20220089581-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-24 | — | — | US | disclosed |
| EP-3914592-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | University of Virginia Patent Foundation (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020154431-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | LYNCH KEVIN R (US) | 2020-07-30 | — | — | WO | disclosed |
| EP-0504574-B1 | 1,2,4-Oxadiazole derivatives having monoamine oxidase B enzyme-inhibitory activity and method for preparing same | WAKAMOTO PHARMA CO LTD (JP) | 1996-02-28 | — | — | EP | disclosed |
| US-5356916-A | Treating Parkinson*s disease | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1994-10-18 | — | — | US | disclosed |
| EP-0504574-A1 | 1,2,4-Oxadiazole derivatives having monoamine oxidase B enzyme-inhibitory activity and method for preparing same | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1992-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089581-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | RAB9A 4302/4885GAA 3521/4885NPC1 420/4885 |
| US-12590083-B2 | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy | SPNS2, SLC20A2, S1PR2 | RAB9A 1729/4885GAA 4800/4885NPC1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.